Download the entire issue - American Association for Clinical ...

2 0 11 N E w P r o d U c T s r E v I E w special section
Advertisement
be performed on a single platform. Singleuse
cartridges are used to perform each and
every extraction on the system, reducing the
risks of analyte carryover and accumulation
of matrix components that can compromise
analytical performance. *For research use
only.
Waters Corporation
www.waters.com/clinical
Booth No. 3136
The NGAL Test*
The NGAL Test, a particle-enhanced
turbidimetric assay for the quantitative
determination of NGAL in human urine or
plasma, is designed for routine diagnostic
use on chemistry analyzers from numerous
manufactures, such as Roche, Abbott,
Siemens, and Beckman Coulter. NGAL is a
novel biomarker for diagnosing acute kidney
injury (AKI). The test effectively gives almost
any laboratory immediate access to a fast and
easy method to measure NGAL. This test is
intended for in vitro diagnostic use in select
countries only. Check for availability in your
country on our website. *For research use
only.
BioPorto Diagnostics A/S
www.bioporto.com
Booth No. 2809
hema-screen SPECIFIC*
hema-screen SPECIFIC is an immunochemical,
fecal, occult-blood test specific for
human hemoglobin. hema-screen SPECIF-
IC’s distinguishing feature is our patented
DEVEL-A-TAB collection slide, allowing
two specimens to be tested at the same time.
The new enhanced version of hema-screen
SPECIFIC contains an additional 10 collection
system/mailing envelopes. This feature
allows doctors or labs to hand out additional
collection system/mailing envelopes to compensate
for non-compliance. Look for our
new packaging. *In development.
Immunostics Inc.
www.immunostics.com
Booth No. 1556
ABO & RhD Blood Grouping kit*
INTEC ABO & RhD Blood Grouping Kit
uses unique visual testing technology to
detect ABO and RhD blood groups based on
the immune response principle of antigens
and antibodies. The kit is suitable for on-site
blood collection, medical laboratory testing,
and urgent pre-transfusion testing. With
rapid accurate results and good performance
in specificity and stability, the kit can be stored
at 2–30ºC for 2 years. The kit offers detection
of ABO and RhD blood groups simultane-
ously in one test without any additional
equipment. This product has international
patent: No.: PCT/CN2009/000322. *Pending
FDA clearance.
InTec PRODUCTS, Inc.
www.intecasi.com
Booth No. 741
BS-800 Modular System*
BS-800 Modular System, an innovative clinical
chemistry diagnostic system manufactured
by Mindray Corporation, incorporates
Mindray’s suggested reagents, calibrators,
and controls. It can be adapted to customers’
needs by integrating one to four modular
units with various throughputs, ranging
from 1,200–4,800 tests/hour. The systems
uses only 100 µL of reagent, takes up to 860
The scientific proof of a technology breakthrough
is not established by a single study. The technology
must be evaluated and the study results duplicated
in numerous settings to be considered scientifically
valid. In the last two years, 50 published studies
by leading diabetes hospitals throughout the world
validate that Nova’s StatStrip glucose sensor
technology dramatically improves accuracy by
reducing hematocrit and other interferences. These
studies have been conducted at some of the most
prestigious diabetes centers in the world including
the Mayo Clinic, John Hopkins University School
of Medicine, University of California Davis
Center for Point of Care Technology, University
of Toronto Sunnybrook Health Sciences Center,
Addenbrooke’s Hospital Cambridge University
Hospitals, UK, WEQAS and University Hospital,
Cardiff, Wales, Isala Klinieken, Netherlands.
Some conclusions:
www.statstrip.com
samples, has 2–8ºC reagent cooling, reagent
bubble detection, and user-friendly operating
software. The system allows labs to focus on
cost-effectiveness, result accuracy, operator
safety, and technology advancement. BS-800
Modular System provides a brand new experience
in laboratory practice and lets labs
Scientific Papers Validate
Nova’s Technology Breakthrough
In Glucose Sensor Accuracy
Nova Multi-Well
Glucose StatStrip ® Technology
Publications and Presentations
Copies of this booklet are available by
contacting Nova Biomedical Tel: 781-894-0800
www.novabiomedical.com
“Here we further demonstrate for the first time that anemia is the primary
cause of glucometer error in hemodynamically stable adult ICU patients
and that eliminating hematocrit error decreases the frequency of hypoglycemia.”
Pidcoke M et al. Crit Care Med 2010
“The new generation StatStrip glucose meter, which has been designed to
compensate for hematocrit and chemical interferences, reduces the likelihood
of erroneous results arising from interference factors that influence current
conventional glucose meters.”
Bewley B et al. Point of Care 2009
“The StatStrip system was not susceptible to hematocrit, ascorbate or maltose
interferences, either alone or in combination with one another. The other
strip meter systems tested were significantly influenced by these interferences.”
Lyon ME. AACC, Annual Meeting 2008
“With the exception of the Nova StatStrip, all meters were affected by
variable hematocrit.”
Mohn B. NZJ Med Lab Sci 2010
United States
GLU
Canada (Cont’d)
Asia
Europe
Europe Cont’d
The Nova StatStrip ® Blood Glucose Meter
Evaluation: Hematocrit Dependency,
Method Comparison, Interfering
Substances and Neonatal Samples
Clinical Evaluation of a Point of Care Device
for Creatinine measurements in the Followup
of Kidney Transplant Patients
Validation of two Point-of-Care Testing
devices for fetal lactate assessment
during labour
Evaluation of the Nova Biomedical
StatStrip ® Glucose Meter
Assessment of the Performance of Handheld
POC Sensors for Measuring
3-Hydroxybutyrate
Four Step Validation Procedure for
Evaluating POCT Meters
Comparison of Four Hospital Based
Glucose Meter Technologies for Accuracy,
Precision and Interferences Encountered
in Hospitalized Patients
An Evaluation of the Analytical
Specificity and Clinical Application of a
New Generation Hospital Based Glucose
Meter in a Dialysis Setting
Improved POC Meter Accuracy for
Monitoring and Managing Glucose Levels
in Dialysis Patients
Nova StatStrip ® Evaluation of a Point-Of-Care (POC) Glucose
Meter Suitable for Use in Complex Tertiary
Care Facilities
Performance of a StatStrip
: Could This Device be used
to Effectively Implement Tight Glycemic
Control and Triage Blood Glucose and
Insulin Management in Critical Illness
An Evaluation of the Analytical
Performance of a New Generation
Hospital Based Glucose Meter in a
Neonatal Care Unit
Reliability of Glucose Meters in Hospitals
in Austria
Performance of the Nova StatStrip
Care Glucose Meter in a Neonatal Intensive
Care Unit
Multi-site Evaluation of Point of Care
Glucose Meters in a Neonatal Intensive
Care Unit
A Multi-Site Analytical Assessment of a
New Hospital POC Glucose Meter for
Accuracy, Precision, Correlation, and
Interferences Encountered in
Hospitalized Patients
® Meter
Comparison of Accuracy of a Glucometer
and a Blood Gas Analyzer in an Adult ICU
Comparison of Accuracy of Three
POC Glucometers in an Adult ICU
Performance Of The Statstrip Glucose Meter
In Inpatient Management Of Diabetes Mellitus
Testování Glukometrů a Jejich Porvnání
Evaluation d’un Nouveau Lecteur de
Glycémie Intégrant une Correction
Automatique de l’Hématocrite
Galatose Interference on POCT Glucose
Analysis
Interference of Hematocrit and Maltose
Plasma Concentrations on the Accuracy of
Different Blood Glucose Measuring Systems
Das Blutzuckermessystem StatStrip ® ist nicht
empfindlich für Interferenzen durch
Hämatokrit oder andere bekannte
Störsubstanzen
Genauigkeit des Blutzuckermess-systems
StatStrip ® Comparison Evaluation of Three
Point-of-Care Glucose Meters with
Neonatal Patient Samples Exhibiting
Varied Hematocrit and Triglyceride
Concentrations
Comparative Testing for Better
Glycemic Control
Accuracy and Reliability of the Nova
StatStrip® Glucose Meter for Real-Time
Blood Glucose Determinations
during Glucose Clamp Studies
Evaluation of the Impact of
Hematocrit and Other
Interference on the Accuracy of
Hospital-Based Glucose Meters
Use of Samples from Indwelling Venous
Catheters for Glucose Meter Testing
Comparison of Four Hospital Based
Glucose Meter Technogies Accuracy,
Precision, and Interference Encountered
in Critically Ill Patient
Evaluation of a New POCT Bedside
Glucose Meter and Strip with Hematocrit
and Interference Corrections
Evaluations of Nova StatStrip
im Vergleich zu anderen
Messsystems und zu einer Standard- Labormethode
Analytical Performance of an Interference-
Resistant Glucose Meter
Suitability Assessment of a New Bedside
Interference Free Glucose System for Use
in Critical Care
® Blood
Glucose Monitoring System in Neonates
Evaluation and Implementation of the
Nova StatStrip® Bedside Glucose
Monitor for Patients Undergoing Cardiopmonary
Bu-pass Graft Surgery (CABG)
Development and Use of a Methodology
for the Evaluation and Implementation of
POCT Devices
RGH’s Method for Evaluation and Implementation
of Data-managed Bedside
Glucose (POCTG) Monitoring
Evaluation of Point of Care Bedside
Glucose Monitors for Use in a Specialty
and Transplant Hospital
Hematocrit Effect Outweighs Other
Sources of Glucometer Error in
Critical Care
Assessing the Performance of Handheld
Glucose Testing for Critical Care
Evaluation of a Glucose Meter with Negligible
Hematocrit or Chemical Interference
Predicted Discrepancies Between Direct
Reading Whole Blood Biosensors and
Central Lab Plasma Methods: Predicting
and Avoiding Medical Error
Estimates of Total Analytical Error in
Consumer and Hospital Glucose Meters
Contibuted by Hematocrit, Maltose and
Ascorbate
Interference Studies with Two
Hospital-Grade and Two Home-Grade
Glucose Meters
see us at the 2011 clin lab expo, booth no. 2923
Canada
Multi-National Sites
200 Prospect Street
Waltham, MA 02454-9141 U.S.A.
TEL: (781) 894-0800 (800) 458-5813
www.novabiomedical.com
® Point of
No. 169 Rev. 1/20/11
CliniCal laboratory news July 2011 25